A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, ≥18 years of age
Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma
Ann Arbour Stage III/IV and bulky II (mass \>10 cm)
At least one bi-dimensionally measurable lesion defined as \>1.5 cm in its largest dimension by CT scan
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Left ventricular ejection fraction ≥50%
Adequate hematologic function
You may not be if
Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy
Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation
Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma
Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment
Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection
Pregnant or lactating women
Clareo Health | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
